Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of nemolizumab in acquired reactive perforating collagenosis
jRCT2021230034Phase 2Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acquired reactive perforating collagenosis (ARPC) comparing Nemolizumab with Placebo (2 arms). Primary endpoint: Peak pruritus numeric rating scale (PP-NRS). Started Dec 2023; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
acquired reactive perforating collagenosis (ARPC)
Beyond the preview
Go deeper on jRCT2021230034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230034.